Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

Abhishek Maiti, Kiran Naqvi, Tapan M. Kadia, Gautam Borthakur, Koichi Takahashi, Prithviraj Bose, Naval G. Daver, Ami Patel, Yesid Alvarado, Maro Ohanian, Courtney D. DiNardo, Jorge E. Cortes, Elias J. Jabbour, Guillermo Garcia-Manero, Hagop M. Kantarjian, Farhad Ravandi

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Fingerprint Dive into the research topics of 'Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences